We are testing a new peptide drug, PEP-010, for patients with recurrent or metastatic solid cancers. The study will evaluate its safety and how well it works alone and with other chemotherapy drugs.
Health conditions and diseases that the clinical trial is designed to study and treat.
Recurrent and metastatic solid cancer refers to cancer that has returned after treatment or has spread from its original site to other parts of the body. This can include various types of solid tumors, such as breast, lung, or colorectal cancer.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.